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a b s t r a c t
A causative association was recently demonstrated between homozygous TREM2 mutations and fron-
totemporal dementia (FTD)-like syndrome and between heterozygous TREM2 exon2 genetic variations
and late-onset Alzheimer’s disease (AD). The objective of this study was to evaluate whether hetero-
zygous TREM2 genetic variations might be associated to the risk of FTD. TREM2 exon 2 was sequenced in a
group of 1030 subjectsdnamely, 352 patients fulﬁlling clinical criteria for FTD, 484 healthy control
subjects (HCs), and 194 patients with AD. The mutation frequency and the associated clinical charac-
teristics were analyzed. We identiﬁed 8 missense and nonsense mutations in TREM2 exon 2 in 24 sub-
jects. These mutations were more frequent in patients with FTD than in HCs (4.0% vs. 1.0%, p ¼ 0.005). In
particular, TREM2 Q33X, R47H, T66M, and S116C mutations were found in FTD and were absent in HCs.
These mutations were associated with either the semantic variant of primary progressive aphasia or the
behavioral variant FTD phenotypes. The FTD and AD groups were not signiﬁcantly different with regard
to TREM2 genetic variation frequency (AD: 2.6%, p ¼ 0.39). Heterozygous TREM2 mutations modulate the
risk of FTD in addition to increasing susceptibility to AD. Additional studies are warranted to investigate
the possible role of these mutations in the pathogenesis of neurodegenerative disorders.
 2014 Elsevier Inc. All rights reserved.
1. Introduction
Frontotemporal dementia (FTD) is a heterogeneous neurode-
generative disorder characterized by behavioral disturbances, lan-
guage impairment, and deﬁcits in executive functions (Seelaar et al.,
2011). On the basis of presenting clinical symptoms, the behavioral
variant of FTD (bvFTD), agrammatic variant of primary progressive
aphasia, and semantic variant of primary progressive aphasia
(svPPA) represent the most common phenotypes (Gorno-Tempini
et al., 2011; Rascovsky et al., 2011).
FTD has a strong genetic background, as suggested by positive
family history in almost 40% of patients, and several monogenic
forms of FTD have been identiﬁed. Mutations within
microtubule-associated protein tau (MAPT) and granulin (GRN)
genes along with repeat expansion of C9orf72 gene represent the
most frequent causes of autosomal dominant inherited disorder
(Rademakers et al., 2012; Rohrer et al., 2011). Despite a giant
step forward in the knowledge of genetic bases of FTD, several
cases even with positive family history remain of unknown
pathogenesis. The identiﬁcation of new genetic predisposing
factors, even rare variants, is key to further elucidating the
pathogenetic mechanisms leading to frontotemporal brain
damage.
Homozygous loss-of-function mutations in TREM2, encoding the
triggering receptor expressed on myeloid cells 2 protein, have been
previously associated with an autosomal recessive form of early-onset
dementia presenting with bone cysts and consequent fractures
called polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy, or Nasu-Hakola disease (Paloneva et al., 2000,
2002). Interestingly, it has been reported that homozygous TREM2
exon 2 mutations may resemble FTD clinical phenotype without any
bone-associated symptoms (Guerreiro et al., 2013a). Nevertheless,
heterozygosis of TREM2 exon 2 mutations also has a role in neuro-
degenerative disorders because it has recently been associated with
increased risk of late-onset Alzheimer’s disease (AD) (Guerreiro et al.,
2013b; Jonsson et al., 2013).
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These observations deﬁned the aim of the present study, and we
hypothesized that variations within TREM2 gene might be associ-
ated with a broader clinical spectrum and might predispose to FTD
phenotype in heterozygous state. We evaluated genetic variations
within TREM2 exon 2 gene in a large cohort of patients with FTD,
compared with healthy control subjects and a group of patients
with AD.
2. Methods
2.1. Subjects
Patients fulﬁlling revised criteria for FTD (Gorno-Tempini et al.,
2011; Rascovsky et al., 2011) were consecutively recruited from
the Center for Aging Brain and Neurodegenerative Disorders, Uni-
versity of Brescia, the Neurology Unit, University of Florence, and
the Neurology Unit, University of Milan, Italy.
All subjects underwent a somatic and neurologic evaluation,
routine laboratory examination, and brain structural imaging
study. A standardized neuropsychological assessment including
global cognitive evaluation and a standardized neuropsychological
test battery for investigating the main cognitive domains was per-
formed. The diagnostic assessment included a review of full med-
ical history, a semistructured neurologic examination, and a
complete mental status evaluation. Patients considered to have a
positive family history were those who had a ﬁrst-degree relative
with dementia, parkinsonism, or motor neuron disease. No patients
belonging to the same family were included. A venous blood sample
was drawn from each patient for TREM2 exon 2 sequencing.
Patients with MAPT or GRN mutations and with repeat expan-
sion of C9orf72 gene were excluded (Borroni et al., 2011; Galimberti
et al., 2013). Moreover, a control group similar in age and gender
composition was recruited in the same Italian area from which the
patients were drawn and was sequenced for TREM2 exon 2 genetic
variations. Two subgroupswere considered for comparisons, that is,
subjects found to be cognitively intact, following medical history,
presence of comorbidities, and neuropsychological examination
(healthy controls [HCs]), and patients fulﬁlling clinical diagnosis of
AD according to current criteria (McKhann et al., 1984).
Informed consent was obtained for blood collection fromvenous
puncture and genetic analysis from each subject. Thework conform
to the Helsinki Declaration and was approved by the ethics com-
mittee of our hospital.
2.2. TREM2 exon 2 sequencing
Total genomic DNA was prepared from peripheral blood ac-
cording to standard procedures. TREM2 exon 2 and at least 100 base
pairs of its ﬂanking introns were evaluated by polymerase chain
reaction (PCR), the primers of which were designed to optimize
denaturing high-performance liquid chromatography (dHPLC)
conditions (forward primer: 50-CACAGAGCAAGTGTTCAAAGC-30
and reverse primer: 50-CACACAGACGCCCAAAAC-30 with the
annealing temperature of 57 C.
Preliminary dHPLC analysis was performed on the Wave nucleic
acid fragment analysis system (Transgenomic, Santa Clara, CA,
USA), and samples with an altered dHPLC proﬁle were sequenced.
Nucleotide direct sequencing was performed on genomic DNA for
both strands by ABI 3130xl DNA analyzer (Applied Biosystems,
Foster City, CA, USA) and analyzed using SeqScape Software version
2.6 (Applied Biosystems, Foster City, CA, USA).
2.3. Bioinformatic analyses
A multiple protein alignment was constructed with multiple
alignment by Bioedit (http://www.mbio.ncsu.edu/bioedit/bioedit.
html) and CLUSTALW (http://clustalw.ddbj.nig.ac.jp/top-e.html)
software.
The potential effect of the newly detected mutations on
protein structure or function was analyzed with 4 prediction pro-
grams: PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), Pmut:
(http://mmb.pcb.ub.es/PMut/), SNAP (http://rostlab.org/services/
snap/), and SIFT (http://sift.jcvi.org/www/SIFT_enst_submit.html).
2.4. Statistical analysis
Comparisons of each mutation and overall mutation frequencies
between patients and HCs were compared by Pearson c2 test. Lo-
gistic regression analysis was performed to assess odds ratio, and
corresponding 95% conﬁdence intervals. Results are expressed as
mean  SD or percentage, as reported. The signiﬁcant level was
established at p < 0.05. Data analyses were carried out using SPSS
13.0 software (http://wwwspss.com).
3. Results
One thousand and thirty subjects were included in the present
study, 352 patients with a diagnosis of FTD (aged 65.6  8.6 years,
48.8% women), and, as control groups, 484 HCs (aged 72.2  10.1
years, 54.5% women) and 194 patients with AD (aged 65.9  7.2
years, 53.1% women).
In the overall sample, we found 8 genetic variations in 24 sub-
jects in 24 subjects: Q33X, R47H, R62H, T66M, D87N, T96K, R98W,
and S116C. As reported in Table 1, R47H, T66M, and S116C were
found only in patients with FTD; Q33X was found in patients with
both FTD and AD, and R62H, D87N, T96K, and R98W were also
found in HCs.
Table 1
TREM2 exon2 genetic variations in the screened population
TREM2 mutation SNP FTD %
(n)
HC %
(n)
AD %
(n)
p
FTD vs. HC
p FTD vs. AD p
AD vs. HC
OR (95% CI)
FTD vs. HC
OR (95% CI)
FTD vs. AD
OR (95% CI)
AD vs. HC
Overall d 4.0 (14) 1.0 (5) 2.6 (5) 0.005 0.393 0.126 3.97 (1.42e11.12) 1.57 (0.56e4.41) 2.53 (0.72e8.85)
Q33Xa rs104894002 0.9 (3) 0 (0) 1.5 (3) 0.042 0.457 0.023 NA 0.54 (0.11e2.74) NA
R47H rs75932628 0.3 (1) 0 (0) 0 (0) 0.241 0.457 d NA NA NA
R62H rs143332484 0.9 (3) 0.4 (2) 0.5 (1) 0.221 0.466 0.637 2.77 (0.50e15.21) 2.22 (0.24e20.00) 1.30 (0.11e13.85)
T66Ma rs201258663 0.3 (1) 0 (0) 0 (0) 0.241 0.457 d NA NA NA
D87N rs142232675 0.6 (2) 0.2 (1) 0 (0) 0.388 0.293 0.714 2.76 (0.29e30.56) NA NA
T96K rs2234253 0.9 (3) 0.2 (1) 0 (0) 0.182 0.197 0.714 4.15 (0.43e40.08) NA NA
R98W rs147564421 0 (0) 0.2 (1) 0.5 (1) 0.393 0.178 0.491 NA NA 2.5 (0.15e40.21)
S116C d 0.3 (1) 0 (0) 0 (0) 0.241 0.457 d NA NA NA
Key: AD, Alzheimer’s disease; CI, conﬁdence interval; FTD, frontotemporal dementia; HC, healthy control subjects; NA, not applicable; OR, odds ratio; SNP, single nucleotide
polymorphism.
a Mutation causative of Nasu-Hakola disease in homozygous state.
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Overall, we found signiﬁcantly more variants in exon 2 of TREM2
in patients with FTD than in HCs (4.0% vs. 1.0%, p ¼ 0.005). Carriers
of TREM2 exon 2 mutations had an almost 4-fold increased risk to
develop FTD than noncarriers (odds ratio: 3.97, 95% conﬁdence
intervals: 1.42e11.12). In FTD, 6 of 14 patients carried heterozygous
TREM2 mutations that were not found in HCs. As reported in
Table 2, in silico analysis demonstrated that the Q33X variant
(cytosine to thymine change in position 6818), previously associ-
ated with Nasu-Hakola disease in the homozygous state, resulting
in a TAG stop codon with a loss of function of the TREM2 protein.
The R47H mutationwas characterized by a single point mutation in
the CGC codon, with the substitution of guanine with adenine, and
was predicted to be damaging in 3 of 4 in silico analyses. The T66M
mutation was characterized by a single point mutation in the ACG
codon, resulting in a replacement of threonine at position 66 with
methionine; all in silico analyses predicted a pathologic effect of
this substitution, and this mutation was previously associated with
Nasu-Hakola disease in homozygosity. S116C has not been previ-
ously described in the literature and causes a substitution of
adenine to thymine; no clear-cut results were obtained by in silico
analysis because 2 of 4 prediction analyses suggested neutral effect.
In Table 3, demographic and clinical characteristics of patients
with FTD carrying TREM2 Q33X, R47H, T66M, and S116C are re-
ported. In most of these cases, patients presented an early age of
onset (range: 52e68 years), and 66.7% were women. Family history
was unremarkable in 5 of 6 patients. Half had a diagnosis of svPPA
(2 Q33X, 1 S116C), and the others had a diagnosis of bvFTD (1 Q33X,
1 R47H, and 1 T66M), with a phenotypic variability in patients
carrying the same genetic variation.
When the AD control group was considered to elucidate
whether FTD and AD may share a common at-risk genetic back-
ground, no signiﬁcant differences in the overall number of TREM2
exon 2 mutations were found (4.0% vs. 2.6, p ¼ 0.46). Notably, in
1.5% of patients with AD (n¼ 3, 2 women, age range 58e69 years), a
heterozygous Q33X mutation was found, whereas 1 patient carried
R62H and 1 carried R98W, both of which were also found in HCs.
Finally, when the AD group was compared with the HC group,
we found signiﬁcantly more Q33X variants of TREM2 in the former
group (n¼ 3,1.5%) then the latter (0.0%, p¼ 0.023). Patients with AD
carrying Q33X mutation showed late-onset disease (aged 65e75
years), 2 of 3werewomen, and none carried the apolipoprotein E ε4
allele.
Moreover, in AD, we found R62H and R98W mutations, which
were detected in HCs as well. We did not ﬁnd any difference in
overall frequency of mutations in patients with AD versus HCs,
presumably because of the small sample of patients with AD.
4. Discussion
TREM2 gene has recently gained great interest in the dementia
ﬁeld, as the identiﬁcation of homozygousmutations in cases of FTD-
like phenotype (Guerreiro et al., 2013a, 2013c), and the demonstra-
tion that TREM2 exon 2 genetic variations are risk factors for AD in
heterozygosis (Guerreiro et al., 2013b; Jonsson et al., 2013). With
these premises, we hypothesized that heterozygous TREM2 muta-
tions might be related to FTD risk as well. In the present work, we
screeneda largesampleof patients andHCs for TREM2exon2genetic
variations and found that FTD patients showed increased frequency
of heterozygousTREM2mutations comparedwithHCs. Interestingly,
we conﬁrmed that Q33X, R47H, and T66M mutations were signiﬁ-
cantly associated with the disease and absent in healthy subjects.
Q33X and T66M mutations have previously been demonstrated to
cause Nasu-Hakola disease in the homozygous state (Paloneva et al.,
2000, 2002), and the heterozygous R47H mutation has been asso-
ciated with AD risk (Guerreiro et al., 2013b; Jonsson et al., 2013).
Accordingly, in silico analysis of these mutations suggested a loss of
function in TREM2; this might suggest that these variants are causal
mutations, even in heterozygosis, rather than risk factors.
Notably, different clinical phenotypes were observed in FTD
patients carrying these TREM2 genetic variations with variable age
at disease onset and inconsistent family history for neurodegen-
erative disorders. Interestingly, patients presented either bvFTD or
svPPA, and this is the ﬁrst association study suggesting a genetic
risk factor for svPPA phenotype.
Recently studies on TREM2 genetic variations have been pub-
lished in France (Lattante et al., 2013), the United States (Rayaprolu
et al., 2013), and Colombia (Giraldo et al., 2013) with different
mutation frequencies. No work exploring the role of TREM2 in the
Italian population is available yet.
TREM2 encodes a single-pass type I membrane protein that
forms a receptor-signaling complex with the TYRO protein tyrosine
kinase-binding protein (TYROBP) that is involved in the activation
of immune responses in immune cells, as macrophages and den-
dritic cells. It is involved in chronic inﬂammation by triggering the
production of constitutive rather than inﬂammatory chemokines
and cytokines and has a critical role in microglia clearance
(Neumann et al., 2013; Paloneva et al., 2003; Takahashi et al., 2005).
Interestingly, we also found TREM2 mutations in our AD pa-
tients, conﬁrming previous data (Guerreito et al., 2013b; Jonsson
et al., 2013) and suggesting a common pathway in these 2 neuro-
logic disorders, likely associated to inﬂammation processes. Indeed,
emerging evidence has underlined a greater interest in mecha-
nisms targeting inﬂammation in both diseases (Galimberti and
Scarpini, 2011; Piguet, 2013). Furthermore, in human control
brain, TREM2 was expressed at higher levels in the hippocampus
and neocortex (Guerreiro et al., 2013a), and this pattern of
Table 2
In silico analyses of the amino acid changes found in the analyzed sample
In silico software Q33X R47H R62H T66M D87N T96K R98W S116C
PolyPhen2 (scorea) Stop gained. NA Probably
damaging (1.0)
Benign (0.016) Probably
damaging (1.0)
Probably
damaging (1.0)
Probably
damaging (1.0)
Probably
damaging (0.995)
Probably
damaging (0.987)
SNAP Stop gained. NA Nonneutral Neutral Nonneutral Neutral Nonneutral Nonneutral Neutral
P-mut Stop gained. NA Pathologic Pathologic Pathologic Neutral Pathologic Pathologic Pathologic
SIFT Stop gained. NA Tolerated Tolerated Damaging Tolerated Damaging Damaging Tolerated
Key: NA, not applicable.
a The lower the score, the more benign the substitution (range 0e1).
Table 3
Demographic and clinical characteristics of FTD patients carrying TREM2 exon 2
mutations
Age at onset Gender Family history Phenotype
ID1 Q33X 68 F No svPPA
ID2 Q33X 52 F No svPPA
ID3 Q33X 53 F Yes bvFTD
ID4 R47H NA M No bvFTD
ID5 T66M 55 M No bvFTD
ID6 S116C 59 F No svPPA
Key: bvFTD, behavioral variant of primary progressive aphasia; NA, not available;
svPPA, semantic variant of primary progressive aphasia.
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expression is partly consistent with pathologic features observed in
both FTD and AD.
The effect of TREM2 genetic variations in FTD cases and the
possible interaction with protein involved in the known pathoge-
netic mechanisms of the disease remains to be elucidated. Func-
tional activity assays will be required to determine how these
identiﬁed mutations might compromise TREM2 function, providing
new clues to the mechanisms underlying the pathogenesis of FTD.
Unfortunately, we were not able to assess the effect of TREM2 ge-
netic variation in our patients because it is expressed only in
microglia and not in circulating monocytes.
This is a preliminary study, and we do not exclude the possibility
that the frequency of heterozygous mutations we found is partially
due to the relatively high number of cases (n¼ 3) with Nasu-Hakola
disease (i.e., homozygous Q33Xmutation) that we diagnosed in our
geographic area (Bock et al., 2013). Moreover, it is reasonable to
suppose that other mutations in TREM2, beyond exon 2, may be
identiﬁed. However, as previously suggested (Guerreiro et al.,
2013b), it may be that rare variants in the heterozygous state may
be risk factors for late-onset complex disorders, determining
deﬁned early-onset disease when in homozygosis.
In conclusion, we report that TREM2 variants might be consid-
ered risk variants in FTD not only in homozygosis as previously
demonstrated but in heterozygosis as well. Moreover, the absence
of certain variants, in both our control population and others pre-
viously published (Guerreiro et al., 2013b; Jonsson et al., 2013;
Paloeva et al., 2001), raises the question of whether such variants
are mutations leading to dementia and Nasu-Hakola disease rather
than polymorphisms inﬂuencing the risk of developing FTD.
Whether TREM2 is a major gene or a modiﬁer gene for FTD and AD
remains to be determined. Future conﬁrmatory clinical and exper-
imental studies are needed to elucidate the role of this gene in FTD.
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